SCHEMBL2560734

SCHEMBL2560734

Cc1cc([N+](=O)[O-])ccc1OCC(F)(F)F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
TDP1 Q9NUW8 3/20 0.50
TSHR P16473 2/20 0.50
CYP3A4 P08684 5/20 0.47
CFTR P13569 1/20 0.44
S1PR4 O95977 2/20 0.43
CYP1A2 P05177 4/20 0.43
CYP2C9 P11712 4/20 0.43
CYP2C19 P33261 4/20 0.43
MPI P34949 2/20 0.42
PHOSPHO1 Q8TCT1 2/20 0.42
PMM2 O15305 1/20 0.42
MAPT P10636 6/20 0.41
HTT P42858 3/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
CYP2D6 P10635 3/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7334388 0.88 ALDH1A1 (0.50) ALDH1A1TDP1TSHRCYP3A4CFTR
SCHEMBL10970839 0.86 MPI (0.47) ALDH1A1TDP1TSHRCYP3A4CFTR
SCHEMBL941299 0.84 ALDH1A1 (0.49) ALDH1A1TDP1TSHRCYP3A4S1PR4
SCHEMBL3506058 0.83 MAPT (0.46) ALDH1A1TDP1TSHRCFTRMAPT
SCHEMBL1772198 0.83 HSPB1 (0.52) ALDH1A1TDP1TSHRCYP1A2MPI
SCHEMBL21497160 0.83 CYP1A2 (0.49) ALDH1A1TDP1CFTRS1PR4CYP1A2
SCHEMBL2563093 0.83 S1PR4 (0.53) ALDH1A1TDP1CFTRS1PR4MPI
SCHEMBL22381241 0.82 ALDH1A1 (0.58) ALDH1A1TDP1TSHRCYP3A4S1PR4
SCHEMBL2568058 0.82 MAPT (0.54) ALDH1A1TDP1CYP3A4CYP1A2CYP2C9
SCHEMBL6704146 0.82 MPI (0.42) ALDH1A1TDP1CFTRS1PR4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210253594-A1 OXADIAZOLOPYRAZINES AND OXADIAZOLOPYRIDINES USEFUL AS MITOCHONDRIAL UNCOUPLERS VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. 2021-08-19 US disclosed
US-20210253594-A1 OXADIAZOLOPYRAZINES AND OXADIAZOLOPYRIDINES USEFUL AS MITOCHONDRIAL UNCOUPLERS VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. 2021-08-19 US disclosed
EP-3781572-A1 OXADIAZOLOPYRAZINES AND OXADIAZOLOPYRIDINES USEFUL AS MITOCHONDRIAL UNCOUPLERS Virginia Tech Intellectual Properties, Inc. (US) 2021-02-24 EP disclosed
CN-112262146-A Oxadiazolopyrazines and oxadiazolopyridines useful as mitochondrial uncouplers 弗吉尼亚理工大学知识产权有限公司 2021-01-22 CN disclosed
WO-2019204813-A1 OXADIAZOLOPYRAZINES AND OXADIAZOLOPYRIDINES USEFUL AS MITOCHONDRIAL UNCOUPLERS VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) 2019-10-24 WO disclosed
WO-2019204813-A1 OXADIAZOLOPYRAZINES AND OXADIAZOLOPYRIDINES USEFUL AS MITOCHONDRIAL UNCOUPLERS VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) 2019-10-24 WO disclosed
EP-2382218-A1 DELTA-5-DESATURASE INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2011-11-02 EP disclosed
WO-2010087467-A1 DELTA-5-DESATURASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-05 WO disclosed
US-20100190747-A1 Fused ring compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210253594-A1 OXADIAZOLOPYRAZINES AND OXADIAZOLOPYRIDINES USEFUL AS MITOCHONDRIAL UNCOUPLERS NDUFAF1, OXA1L, GLS2 ALDH1A1 474/4885TDP1 2801/4885TSHR 1962/4885
US-20100190747-A1 Fused ring compound and use thereof CYP46A1, LTB4R2, PTGES ALDH1A1 875/4885TDP1 3961/4885TSHR 4543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.